$7.23
6.35% day before yesterday
Nasdaq, Jan 02, 10:05 pm CET
ISIN
US92337C1045
Symbol
VSTM

Verastem, Inc. Stock price

$7.23
-2.55 26.07% 1M
+2.38 49.07% 6M
-0.49 6.35% YTD
+0.74 11.40% 1Y
+2.40 49.69% 3Y
-19.17 72.61% 5Y
-14.13 66.15% 10Y
-125.85 94.57% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.49 6.35%
ISIN
US92337C1045
Symbol
VSTM
Industry

Key metrics

Basic
Market capitalization
$544.6m
Enterprise Value
$495.5m
Net debt
positive
Cash
$137.7m
Shares outstanding
66.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
40.7 | 17.6
EV/Sales
37.0 | 16.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-28.5%
Return on Equity
452.1%
ROCE
-99.1%
ROIC
-
Debt/Equity
-5.7
Financials (TTM | estimate)
Revenue
$13.4m | $30.9m
EBITDA
$-115.7m | -
EBIT
$-116.1m | $-170.7m
Net Income
$-189.0m | $-214.5m
Free Cash Flow
$-140.9m
Growth (TTM | estimate)
Revenue
33.8% | 208.5%
EBITDA
-33.8% | -
EBIT
-34.3% | -48.5%
Net Income
-217.2% | -64.2%
Free Cash Flow
-28.8%
Margin (TTM | estimate)
Gross
85.1%
EBITDA
-864.4% | -
EBIT
-867.6%
Net
-1,412.7% | -695.4%
Free Cash Flow
-1,053.4%
More
EPS
$-2.6
FCF per Share
$-2.1
Short interest
22.3%
Employees
78
Rev per Employee
$130.0k
Show more

Is Verastem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Verastem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Verastem, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Verastem, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Verastem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
13 13
34% 34%
100%
- Direct Costs 1.99 1.99
-
15%
11 11
-
85%
- Selling and Administrative Expenses 52 52
69% 69%
392%
- Research and Development Expense 75 75
14% 14%
557%
-116 -116
34% 34%
-864%
- Depreciation and Amortization 0.42 0.42
2,000% 2,000%
3%
EBIT (Operating Income) EBIT -116 -116
34% 34%
-867%
Net Profit -189 -189
217% 217%
-1,413%

In millions USD.

Don't miss a Thing! We will send you all news about Verastem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verastem, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Verastem, Inc. is downgraded from Strong Buy" to Buy following discontinuation of its RAMP-203 G12C NSCLC study. VSTM pivots focus to VS-7375, an oral KRAS G12D "ON/OFF" inhibitor, with promising early efficacy and safety data in KRAS G12D NSCLC patients. Upcoming interim phase 1/2a U.S. data for VS-7375 in KRAS G12D solid tumors, expected 1H 2026, is a major catalyst.
Neutral
Business Wire
5 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical devel...
Neutral
Business Wire
19 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will join the...
More Verastem, Inc. News

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Head office United States
CEO Dan Paterson
Employees 78
Founded 2010
Website www.verastem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today